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Gabapentin has been accepted worldwide as a novel antiepileptic drug with a favourable tolerability profile. However, 
movement disorders have been reported previously as rare side-effects in individual patients. 
We report on two patients who developed isolated severe ataxia under low-dose gabapentin which resolved abruptly after 
discontinuation of the drug. This side-effect probably resembled a rare idiosyncratic adverse reaction. 
We propose the gabapentin-specific neuronal binding site which has a high density in the cerebellum as a possible mech- 
anism of action and suggest that the initiation of gabapentin requires caution if pre-existing cerebellar function impairment 
is evident. 
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INTRODUCTION 
Gabapentin (GBP) has been introduced and mar- 
keted in several countries worldwide as an additional 
antiepileptic drug (AED) for treatment of intractable 
localization-related epilepsies. Beyond its proven effi- 
cacy, its very favourable safety and tolerability profile 
has been emphasized repeatedly. Several authors have 
reported movement disorders as rare GBP-specific 
side-effects which included dystonia, myoclonus, and 
choreoathetotic movements’**. Although the compar- 
atively low risk of adverse treatment effects under 
GBP3s4 is consistent with our clinical experiences in 
most patients, dose-independent and almost selective 
ataxia occurred in two of our patients which abruptly 
disappeared after discontinuation of GBP and which 
appeared to represent a further unusual but specific 
idiosyncratic adverse reaction to GBP. 
CASE REPORTS 
Case 1 
This 28-year-old female had suffered from drug- 
resistant localization-related epilepsy with epigas- 
tric auras, complex-partial and secondary general- 
ized seizures since the age of 11. Monotherapies 
with slow-release carbamazepine up to 2800 mg/day 
and with phenytoin up to 500 mglday had been 
shown not to be satisfactory since the seizure fre- 
quency remained stable at around 10 complex-partial 
seizures/month. Various drug combinations tried in- 
cluded carbamazepine and phenytoin as well as carba- 
mazepine combined with valproate, phenobarbitone, 
lamotrigine and vigabatrin, respectively. We therefore 
decided to add GBP to the established monotherapy 
with carbamazepine. Gabapentin was started with a 
daily dose of 300 mg/day. In spite of this cautious 
regimen, the patient presented with severe gait and 
postural ataxia without considerable additional neu- 
rotoxic symptoms the day after introduction of GBP. 
The ataxia was so prominent that the patient was not 
able to move without help and would fall repeatedly. 
Since no other interfering factor became obvious, we 
discontinued GBP after one week with complete loss 
of all ataxic symptoms within 1 day. 
Case 2 
This 24-year-old male had presented to our epilepsy 
unit as an outpatient referral because of drug-resistant 
epilepsy. Previous unsatisfactory drug treatment had 
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included monotherapies with carbamazepine and val- 
proate as well as the combination of these two AEDs. 
Due to sedative effects of the drug, the patient had 
discontinued carbamazepine two weeks before he was 
referred. On referral he presented with up to six 
complex-partial seizures a day which indicated elec- 
troclinical findings of video-EEG originating from the 
frontal lobe. The aetiology remained unclear since 
early history and neuroimaging with magnetic res- 
onance imaging (MRI) and single photon emission 
computer tomography gave no hints in this respect. 
However, MRI revealed cerebellar atrophy mainly of 
the vermis which corresponded well with the patient’s 
slight gait ataxia in spite of his medication-free sta- 
tus at referral. Since rapid initiation of AED treatment 
was as necessary as a well-tolerated regimen we de- 
cided not to try phenytoin, which would have been 
the first choice without the patient’s cerebellar symp- 
toms, but to establish treatment with GBP due to its 
favourable safety profile. Under the starting dose with 
300 mg/day he developed marked cerebellar symp- 
toms including massive gait ataxia, dysarthric speech 
and nystagmus as the most prominent findings. As 
seizure frequency clearly declined, GBP was contin- 
ued for 5 days. However, cerebellar symptoms con- 
tinued to the extent that we had to replace GBP treat- 
ment rapidly. Under monotherapy with lamotrigine 
on day 6 and 1 day after abrupt discontinuation of 
GBP, marked amelioration was apparent. A day later 
the previous status had been regained, although lam- 
otrigine had been increased to 200 mg/day. 
DISCUSSION 
Recent posturographic recordings in healthy volun- 
teers gave evidence for consistent increases of body- 
sway velocity and amplitude after a single oral dose 
of 1200 mg of GBP which was indicative of a specific 
drug-related effect since comparable effects were not 
B. J. Stelnhoff et a/ 
registered after carbamazepine, valproate, vigabatrin, 
lamotrigine and losigamone, respectively5. Since pre- 
clinical receptor-binding studies demonstrated a high 
cerebellar affinity of the GBP-specific neuronal bind- 
ing site in the cortex6, one may speculate whether this 
novel mechanism of action is responsible for these re- 
sults and for the rare but drug-specific side-effect we 
noticed in our patients and which has not been re- 
ported previously. In our experience, this side-effect 
had an incidence of 3% since 67 of a total of 1657 pa- 
tients have been treated with GBP in our out-patient 
department since the marketing of the drug in Ger- 
many. An unusual receptor-binding behaviour under 
GBP is proposed as a possible explanation for the id- 
iosyncratic ataxia we observed. This view is strength- 
ened by the rapid and complete remission after with- 
drawal of GBP. In our experience, the development 
of marked and almost isolated cerebellar dysfunction, 
even under low dosages of GBP, should raise the sus- 
picion of GBP-specific ataxia and warrants the dis- 
continuation of the drug. 
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